BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia

BioNexus Gene Lab Corp

BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.
VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.
Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.
Conditions include IP license agreement; other definitive agreements not yet executed.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

BioNexus Gene Lab Corp issued restricted shares representing 19.9% of its outstanding common stock of common stock to Fidelion Diagnostics Pte. Ltd..

Security: common stock
Shares: restricted shares representing 19.9% of its outstanding common stock
Purchaser: Fidelion Diagnostics Pte. Ltd.

Exact text from the filing

In connection with the SSSA, upon completion the Company will issue restricted shares representing 19.9% of its outstanding common stock to Fidelion as consideration for the Company’s subscription of Fidelion shares.

View on SEC.gov

Browse all equity issuances →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-008044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.